Nightingale Health's mission is to build sustainable healthcare and reduce health inequalities. They have developed the world’s most advanced health check for the health industry, providing risk detection for multiple chronic diseases from a single blood sample. Their solution is scalable to entire populations at a low cost and can replace many current risk assessments. Detecting disease risks at a population level allows for effective targeting and tracking of health interventions and better prevention of chronic diseases onset.

Nightingale Health operates globally with a parent company in Finland and subsidiaries in Japan, the United States, Singapore, Germany, Estonia, Sweden, and the United Kingdom. They have customers in more than 25 countries in healthcare and medical research sectors. Their technology is used in leading health initiatives such as the UK Biobank and is validated by over 600 peer-reviewed publications.

- Finland: Nightingale Health Plc (HQ & Laboratory in Helsinki and a laboratory in Kuopio)
- Estonia: Nightingale Health Estonia OÜ in Tallinn
- Germany: Nightingale Health Germany GmbH in Berlin
- Japan: Nightingale Health Japan KK Welltus Inc (office & laboratory in Tokyo)
- Singapore: Nightingale Health Asia Pte. Ltd. in Singapore
- Sweden: NG Health Sweden AB in Stockholm
- United Kingdom: Nightingale Health UK Limited in London
- United States: Nightingale Health United States, Inc. (office in Williamsville, NY)